Clinical trials: Cardiomyopathy, Secondary
Cardiomyopathy, Dilated, Cardiomyopathies, Secondary
Characterization of Irreversible Myocardial Injury in Cardiomyopathies by Contrast-enhanced CMR
Different studies have shown that fibrosis of the heart increases the risk for a sudden death from e.g. arrhythmias. Magnetic Resonance Imaging (CMR) can easily identify even small areas of fibrosis in the heart muscle after…
- Trial name
- NCT00549861
- Testing
- Cardiac Magnetic Resonance study
- Where
- Canada
- Volunteers
- 40 people
- Sponsor
- Oliver Strohm
Rheumatic Fever, Valvular Heart Diseases
Improving Management and Secondary Prevention Through Azithromycin Comparative Trial in Rheumatic Heart Disease in Nigeria)- IMPACT-RHD Nigeria
Background: Nigeria, among other Low and Middle-income countries, bears one of the highest burdens of RHD in Africa, affecting young to middle-aged adults within their productive years.
- Conditions
- Rheumatic Fever, Valvular Heart Diseases, Valvular Cardiomyopathy
- Trial name
- IMPACT-RHD (NCT07625228)
- Testing
- Benzathine Penicillin, Azithromycin (Azithro)
- Volunteers
- 474 people
- Sponsor
- Ladoke Akintola University of Technology, Ogbomoso, Nigeria
Duchenne Muscular Dystrophy, Cardiomyopathy
HOPE-Duchenne (Halt cardiomyOPathy progrEssion in Duchenne)
Male participants with cardiomyopathy secondary to Duchenne muscular dystrophy (DMD) meeting all inclusion and no exclusion criteria will be randomized. All participants will be at least 12 years of age.
- Trial name
- HOPE (NCT02485938)
- Testing
- Allogeneic Cardiosphere-Derived Cells (CAP-1002)
- Where
- 3 sites in United States
- Volunteers
- 25 people
- Sponsor
- Capricor Inc.
Friedreich Ataxia, Cardiomyopathy, Secondary
Study of LX2006 Gene Therapy in Friedreich Ataxia Cardiomyopathy
The purpose of Study LX2006-03, a multicenter, Phase 2, open-label, randomized, controlled study, is to evaluate the efficacy and safety of LX2006 gene therapy in participants with Friedreich ataxia (FA) cardiomyopathy (CM).
- Trial name
- SUNRISE-FA 2 (NCT07721025)
- Testing
- LX2006, Usual Care
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Lexeo Therapeutics